LLY

1,057.79

-1.63%↓

JNJ

205.59

-0.49%↓

ABBV

224.87

-1.27%↓

UNH

323.52

-1.98%↓

AZN

90.48

-2.43%↓

LLY

1,057.79

-1.63%↓

JNJ

205.59

-0.49%↓

ABBV

224.87

-1.27%↓

UNH

323.52

-1.98%↓

AZN

90.48

-2.43%↓

LLY

1,057.79

-1.63%↓

JNJ

205.59

-0.49%↓

ABBV

224.87

-1.27%↓

UNH

323.52

-1.98%↓

AZN

90.48

-2.43%↓

LLY

1,057.79

-1.63%↓

JNJ

205.59

-0.49%↓

ABBV

224.87

-1.27%↓

UNH

323.52

-1.98%↓

AZN

90.48

-2.43%↓

LLY

1,057.79

-1.63%↓

JNJ

205.59

-0.49%↓

ABBV

224.87

-1.27%↓

UNH

323.52

-1.98%↓

AZN

90.48

-2.43%↓

Начало・Списък с акции・Biogen Inc

Biogen Inc

Затворен

СекторЗдравеопазване

177.6 -2.42

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

175.55

Максимум

181.46

Ключови измерители
By Trading Economics
Приходи	-168M 467M
Продажби	-191M 2.5B
P/E Средно за сектора	16.119 79.874
EPS	4.81
Марж на печалбата	19.004
Служители	7,605
EBITDA	-184M 827M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+1.05% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	3.9B 26B
Предишно отваряне	180.02
Предишно затваряне	177.6

Настроения в новините

By Acuity

44%

56%

155 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Weak Bearish Evidence

118.15 / 121.17 Подкрепа & съпротива

Biogen Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

1.12.2025 г., 21:16 ч. UTC

Придобивния, сливания и поглъщания

Marsh McLennan Agency Acquires Three Hawaii-Based Insurance Brokerages

1.12.2025 г., 18:51 ч. UTC

Значими двигатели на пазара

Shopify Stock Falls on Cyber Monday System Outages

1.12.2025 г., 23:47 ч. UTC

Пазарно говорене

Nikkei May Rise on Bargain Hunting -- Market Talk

1.12.2025 г., 23:27 ч. UTC

Придобивния, сливания и поглъщания

Genting Bhd. Stake in Genting Malaysia Now at 73.13% Vs. 49.36% Ahead of Take Private Offer Made in October

1.12.2025 г., 23:26 ч. UTC

Придобивния, сливания и поглъщания

Genting Bhd.: Offer to Take Genting Malaysia Private Closed on Dec.1

1.12.2025 г., 23:25 ч. UTC

Придобивния, сливания и поглъщания

Bitcoin Rout Picks Up Steam as Investors Fret Over a New 'Crypto Winter' -- WSJ

1.12.2025 г., 21:52 ч. UTC

Придобивния, сливания и поглъщания

Wood Partners Announces Itochu Corp. Purchase of 19.5% of Wood Partners

1.12.2025 г., 21:42 ч. UTC

Придобивния, сливания и поглъщания

Goldman's Latest Acquisition Is a $2 Billion Bet on Active ETFs -- Barrons.com

1.12.2025 г., 21:41 ч. UTC

Пазарно говорене

Canada's GDP Revisions Mean Lower Debt-to-GDP Ratio, Better Productivity -- Market Talk

1.12.2025 г., 21:41 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

1.12.2025 г., 21:41 ч. UTC

Пазарно говорене

Canada's GDP Revisions Mean Lower Debt-to-GDP Ratio, Better Productivity -- Market Talk

1.12.2025 г., 21:17 ч. UTC

Придобивния, сливания и поглъщания

Commercial Metals Expects to Close Foley Products Deal by End of 2025 >CMC

1.12.2025 г., 21:17 ч. UTC

Придобивния, сливания и поглъщания

Commercial Metals Completes Acquisition of Concrete Pipe & Precast for $675M Cash >CMC

1.12.2025 г., 21:15 ч. UTC

Придобивния, сливания и поглъщания

Commercial Metals Completes Acquisition Of Concrete Pipe & Precast, LLC >CMC

1.12.2025 г., 20:15 ч. UTC

Пазарно говорене

Natural Gas Turns Positive Amid Mixed Weather Trends -- Market Talk

1.12.2025 г., 20:00 ч. UTC

Придобивния, сливания и поглъщания

Marsh McLennan Agency Acquires Three Hawai'i-based Insurance Brokerages >MMC

1.12.2025 г., 18:54 ч. UTC

Пазарно говорене

Silver Hits New Record As Momentum Continues -- Market Talk

1.12.2025 г., 18:46 ч. UTC

Пазарно говорене

Luxury Seen With Accelerating Growth Next Year -- Market Talk

1.12.2025 г., 16:41 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

1.12.2025 г., 16:41 ч. UTC

Пазарно говорене

Rapid Wage Growth in Canada to Keep BOC Sidelined -- Market Talk

1.12.2025 г., 16:20 ч. UTC

Пазарно говорене

Yen Could Strengthen Further Against Dollar on Rate-Hike Prospects -- Market Talk

1.12.2025 г., 16:00 ч. UTC

Печалби

Strategy Helped Solve Its Bitcoin-Preferred Problem. Here's How. -- Barrons.com

1.12.2025 г., 15:51 ч. UTC

Придобивния, сливания и поглъщания

Goldman Makes a $2 Billion Bet on 'Boomer Candy' -- WSJ

1.12.2025 г., 15:47 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

1.12.2025 г., 15:47 ч. UTC

Пазарно говорене

Airbus Guidance Is at Risk -- Market Talk

1.12.2025 г., 15:46 ч. UTC

Придобивния, сливания и поглъщания

Synopsys Gets a New Investor. What to Know About Nvidia's Stake. -- Barrons.com

1.12.2025 г., 15:33 ч. UTC

Пазарно говорене

Airbus Selloff May Be Overdone -- Market Talk

1.12.2025 г., 15:26 ч. UTC

Пазарно говорене

Warming Forecast Pressures Natural Gas -- Market Talk

1.12.2025 г., 15:23 ч. UTC

Пазарно говорене

Geopolitical Turmoil Supports Crude Oil -- Market Talk

1.12.2025 г., 14:59 ч. UTC

Придобивния, сливания и поглъщания

Goldman's Latest Acquisition Is a $2 Billion Bet on Active ETFs -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Biogen Inc Прогноза

Ценова цел

By TipRanks

1.05% нагоре

12-месечна прогноза

Среден 184 USD 1.05%

Висок 250 USD

Нисък 149 USD

Според 22 анализатори от Wall Street, предложили 12-месечна ценова цел за Biogen Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

22 ratings

Купи

Задържане

Продай

Според 22 анализатори, дали борсови рейтинги на Biogen Inc през последните 3 месеца.

Техническа оценка

By Trading Central

118.15 / 121.17Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Настроение

By Acuity

155 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.